Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 6/20 | 0.69 |
| ▸ | CNR2 | P34972 | 11/20 | 0.54 |
| ▸ | CNR1 | P21554 | 10/20 | 0.54 |
| ▸ | GBA1 | P04062 | 1/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6606123 | 0.94 | FAAH (0.67) | FAAHCNR2CNR1GBA1 | |
| SCHEMBL13175787 | 0.93 | FAAH (0.62) | FAAHCNR2CNR1GBA1HSP90AA1 | |
| SCHEMBL19154742 | 0.91 | FAAH (0.60) | FAAHCNR2CNR1GBA1HSP90AA1 | |
| SCHEMBL27405108 | 0.91 | FAAH (0.60) | FAAHCNR2CNR1GBA1 | |
| SCHEMBL8599031 | 0.90 | FAAH (0.59) | FAAHCNR2CNR1GBA1 | |
| SCHEMBL8599036 | 0.90 | FAAH (0.59) | FAAHCNR2CNR1GBA1 | |
| SCHEMBL3963145 | 0.90 | FAAH (0.58) | FAAHCNR2CNR1GBA1 | |
| SCHEMBL19957328 | 0.90 | FAAH (0.58) | FAAHCNR2CNR1GBA1 | |
| SCHEMBL8596047 | 0.89 | FAAH (0.58) | FAAHCNR2CNR1GBA1HSP90AA1 | |
| SCHEMBL8599735 | 0.89 | FAAH (0.58) | FAAHCNR2CNR1GBA1HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11091428-B2 | Antiviral compounds | HAPLOGEN GMBH (AT) | 2021-08-17 | — | — | US | disclosed |
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | LUNIS CONSULTING GMBH (AT) | 2019-07-25 | — | — | US | disclosed |
| US-9884814-B2 | Acylguanidines for treating osteoarthritis | MERCK PATENT GMBH (DE) | 2018-02-06 | — | — | US | disclosed |
| US-20150361037-A1 | ACYLGUANIDINES FOR TREATING OSTEOARTHRITIS | MERCK PATENT GMBH (DE) | 2015-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | PLA2G1B, PLA2G12A, PLA2G4C | FAAH 906/4885CNR2 2339/4885CNR1 1319/4885 |
| US-20150361037-A1 | ACYLGUANIDINES FOR TREATING OSTEOARTHRITIS | CTSG, CTSD, CTSB | FAAH 27/4885CNR2 182/4885CNR1 218/4885 |
| US-11091428-B2 | Antiviral compounds | PLA2G1B, PLA2G12A, PLA2G4C | FAAH 906/4885CNR2 2339/4885CNR1 1319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.